These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

14 related articles for article (PubMed ID: 37433433)

  • 1. The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
    Dummer R; Welti M; Ramelyte E
    J Transl Med; 2023 Aug; 21(1):529. PubMed ID: 37543586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utilization of olaparib, a PARP inhibitor, in
    Jiang R; Liang X; Tao Y; Xia R; Lei M; Jiang B; Judson-Torres RL; Zhang Y; Zhang W; Zeng H
    Genes Dis; 2023 Sep; 10(5):1755-1758. PubMed ID: 37492699
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma.
    Phillipps J; Nassief G; Morecroft R; Adeyelu T; Elliott A; Abdulla F; Vanderwalde A; Park S; Butt O; Zhou A; Ansstas G
    NPJ Precis Oncol; 2024 Sep; 8(1):187. PubMed ID: 39232122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in melanoma: advances, pitfalls, and future perspectives.
    Sorino C; Iezzi S; Ciuffreda L; Falcone I
    Front Mol Biosci; 2024; 11():1403021. PubMed ID: 39086722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification.
    Nassief G; Butt OH; Zhou AY; Ansstas G
    JAAD Case Rep; 2024 Jun; 48():59-61. PubMed ID: 38778889
    [No Abstract]   [Full Text] [Related]  

  • 6. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
    Pawlyn C; Loehr A; Ashby C; Tytarenko R; Deshpande S; Sun J; Fedorchak K; Mughal T; Davies FE; Walker BA; Morgan GJ
    Leukemia; 2018 Jul; 32(7):1561-1566. PubMed ID: 29467487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
    Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity.
    Zhou A; Butt O; Ansstas M; Mauer E; Khaddour K; Ansstas G
    J Natl Compr Canc Netw; 2023 Jul; 21(7):688-693.e3. PubMed ID: 37433433
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.